News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy -Cell Stress and Immunity Lab
Photo from Cell Stress and Immunity Lab/X
Jul 23, 2024, 00:19

TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy -Cell Stress and Immunity Lab

Cell Stress and Immunity Lab posted on X about recent paper by Isaure Vanmeerbeek et al., commenting:

“Thrilled to share our lab’s latest research on unique, evolutionarily conserved, TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy!”

Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy

Journal: Science Advances

Author: Isaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, Raquel S. Laureano,  Jannes Govaerts, Rosa Trotta, Samantha Pretto, Shikang Zhao, Sarah Trusso Cafarello, Joren Verelst, Maarten Jacquemyn, Martyna Pociupany, Louis Boon, Susan M. Schlenner, Sabine Tejpar, Dirk Daelemans, Massimiliano Mazzone, Abhishek D. Garg

TIM3+VISTA+ macrophage subset that mediates resistance to anticancer, Immunotherapy and chemotherapy -Cell Stress and Immunity Lab

Source: Cell Stress and Immunity Lab/X

Abhishek D. Garg Cell Stress and Immunity Lab Isaure Vanmeerbeek Jenny Sprooten Massimiliano Mazzone Stefan Naulaerts TIM3+VISTA+ macrophage
Special Coverage
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe